RecruitingNCT05457465

Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolarity

Medication studyAges 18–65United States

The study in practice

Understand this study

This study is for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateStarted: June 1, 2023

Recruitment status: Recruiting
Enrollment listed in the registry: 25
Sponsor: Mclean Hospital
Sponsor type: Hospital / academic medical center
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 2
Locations: United States
Age range: From 18 Years to 65 Years
Official registry ID: NCT05457465
Official title: Show the full official title
Assessing the Impact of Cannabidiol for Anxiety and Depression in Bipolar Disorder

Leave your email and we’ll get in touch to discuss your questions and possible next steps.

Recruiting

Belmont

A listed location does not confirm current availability.

FAQ

Who is behind this study?

The study sponsor is Mclean Hospital, a hospital or academic medical center.

Does this study involve medication?

Yes. The study involves medication, including Cannabidiol.

Who can participate?

This study is for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as recruiting.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.